The question here is simple: which parts of this product are genuinely hard, and which parts are mostly a very profitable coordination habit?
obesity medicine
Once-weekly tirzepatide injection for chronic weight management in adults with obesity or overweight with weight-related conditions, with an additional U.S. approval for obstructive sleep apnea in adults with obesity.
Zepbound extends Lilly's tirzepatide franchise into obesity and sleep-apnea treatment, making it one of the most important products behind the company's recent growth and market narrative.
Replacement sketch
Alternatives
These alternatives are not always drop-in replacements. They do, however, show where the incumbent's pricing power starts facing open pressure.
Disruptive concepts
These are not just existing alternatives. They are structured product ideas for how open coordination, Bitcoin rails, or decentralized production could attack the incumbent's capture points.
A disruption concept would overstate the maturity of open or decentralized alternatives in prescription obesity therapeutics. The actual market remains governed by regulatory approval, molecule-level IP, clinical data, reimbursement access, and manufacturing scale rather than by federated or peer-to-peer coordination.
Technology waves
These are the repo's explicit bias terms: the technologies expected to keep making incumbents less inevitable over time.
Sources
Primary source for company business description, 2025 revenue, 2025 net income, product concentration, and tirzepatide revenue disclosures.
Used for Zepbound indication and prescription-product framing.
Used for Zepbound approval context and mechanism description.